WE ARE
A preclinical with a novel breakthrough therapeutic studied for treating cancer and fibrosis. Our world leading SMAD3 IP is backed by US patent markush rights with other coverage on a global footprint of over 7 billion people, and 10 different cancers with a potential annual market share worth more $125 billion. Our rights includes applications for, co-active use, and other unexplored therapeutic areas.

WE HELP
Unmet medical needs in many cancers, fibrotic diseases and new applications with our novel small molecule TGF-β SMAD3 singling inhibitors.

WE ARE ON THE MOVE
Our AI platform has built the first successful 3D digital scaffold of the SMAD 2, 3, 4 heterotrimer. Our dynamic digital cellular interaction modeling allows for more efficient drug development and testing as we progress though IND. Our path to clinic happens in a shorter time and at a lower costs with the support of our AI innovations.

OUR VALUE PROPOSITION
We are the only known small molecule in the TGF-β therapeutic sector with a SMAD3 inhibitor in advanced development that is secured with global IP. Pharma has committed over $59 billion to discover new and related therapeutics in this sector. Pharma spending includes $11.5 billion to acquire a large molecule fusion protein TGF-β inhibitor, with comparable downstream SMAD signaling. That product is applied for fibrotic treatments.

Our multi-use MoA solution works downstream without inhibiting the TGF-β pathway. Our small molecule products circumvent legacy side-effects related to TGF-β toxicity that is associated with pathway inhibition, and as is commonly identified with large molecules and fusions protein inhibitors.

Our in-vivo studies show broad promise in successfully treating both cancer and fibrosis, and with other potential therapeutic applications actively being investigated.

TGF-β Signaling Regulates Cancer & FibrosisOur SMAD3 Therapeutics Successfully Treats Cancer & Fibrosis

TGF-β cytokines regulate cell fate decisions during development, tissue homeostasis and regeneration, and are major players in tumorigenesis, fibrotic disorders, immune malfunctions and various congenital diseases.

Effects of the TGF-β family are mediated by a combinatorial set of ligands and receptors and by a common set of receptor-activated mothers against decapentaplegic homologue (Smad) transcription factors.

Suppression of NK cell-mediated immuno surveillance via the Smad3-E4BP4 axis contributes to tumor development, cancer progression and fibrosis. Disruption of Smad3 is shown to reverse these effects.

Moexa’s TGF-β SMAD3 therapeutic has secured world leading IP status and is identified as a novel first-in-class solution with potential to bring new drugs therapies for both cancer and fibrosis.

 
MOEXA’S OWNS SMALL MOLECULE TGFB – SMAD3 INHIBITOR TECHNOLOGY that has been proven in animal studies to effectively kill cancer cells with minimal toxicity indications. The therapy has been shown to also treat fibrosis and is secured by world leading IP for both cancer and fibrosis in all major markets. The company is completing IND to prepare for first-in-human clinical trials.

Leadership

Latest News